Study of Skeletal Disorders and Short Stature
NCT00001754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2008-03-04
Summary
This study will determine the genes responsible for skeletal dysplasias (disorders of the skeleton) and short stature and define the range and type of medical problems they cause over time. It will investigate whether specific gene changes cause specific medical problems in these disorders and identify the signs and symptoms upon which their diagnoses must be based.
Individuals with short stature or with a skeletal dysplasia known or suspected to be caused by a gene mutation (change) may be eligible for this study. Family members may also participate. Skeletal dysplasias under study include: achondroplasia, hypochondroplasia, achondrogenesis type II, hypochondrogenesis, Kniest dysplasia, spondyloepiphyseal dysplasias, Stickler syndrome; Shmid and Jansen metaphyseal dysplasias; pyknodysotosis, proximal symphalangism, brachydactyly types B C and E, Ellis van Creveld and related disorders, metatrophic chondrodysplasias, cartilage-hair hypoplasia and disorders with a skeletal abnormality that have not yet been defined but might be the result of a genetic defect.
Patients will talk with two genetics specialists who will explain the study and its possible implications for the patient and family and answer questions. The patient's medical records will be reviewed, a personal and family history will be taken, and a physical examination will be done. Various other procedures that may be done include drawing up to 6 tablespoons of blood, some of which will be used for DNA (genetic) studies, X-rays, echocardiography (ultrasound of the heart), magnetic resonance imaging (MRI), eye examination, hearing test, sleep study, sperm analysis and skin biopsy (surgical removal of a small piece of skin done under local anesthetic). There may be additional evaluations by specialists in rheumatology, rehabilitation medicine and orthopedics. When the tests and examinations are completed (after 2 to 3 days), a doctor will discuss the results with the patient. Patients whose DNA studies show that a gene change is responsible for their disorder will meet with a genetics nurse or counselor to review the results, express their feelings and ask any questions they may have. Patients may be asked to return to NIH every 6 months to 2 years for continued follow-up. Medical management will be provided primarily by the patient's own physician.
Participating family members will be interviewed by telephone about their personal and family health history and will have a blood sample drawn for DNA testing. If a gene change is found that is responsible for the bone disorder or growth problem in the family, arrangements will be made for the family member to discuss the implications of the findings with a genetics specialist.
Conditions
- Developmental Bone Disease
- Dwarfism
- Skeletal Dysplasias
Sponsors & Collaborators
-
National Human Genome Research Institute (NHGRI)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-06-30
- Completion
- 2001-05-31
Countries
- United States
Study Locations
More Related Trials
-
Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00001305 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947 ·Status: RECRUITING
-
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979 ·Status: RECRUITING
-
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
NCT01603095 ·Status: COMPLETED
-
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
NCT03875534 ·Status: COMPLETED
-
Natural History Study of Patients With Excess Androgen
NCT00250159 ·Status: RECRUITING
-
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
NCT01786902 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
NCT05382637 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
NCT00174187 ·Status: TERMINATED ·Phase: PHASE3
-
Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
NCT05858606 ·Status: RECRUITING ·Phase: NA
-
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
NCT00174421 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Nutrition and Hormones in Boys With Disordered Growth
NCT00102258 ·Status: COMPLETED ·Phase: PHASE2
-
C-Type Natriuretic Peptide and Achondroplasia
NCT01541306 ·Status: COMPLETED
-
Skeletal Muscle Effects of GH in Boys
NCT04020913 ·Status: COMPLETED
-
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00266656 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Growth Hormone in Children With Growth Hormone Deficiency
NCT00262249 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
NCT00473187 ·Status: UNKNOWN ·Phase: PHASE1
-
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
NCT01052623 ·Status: UNKNOWN ·Phase: PHASE4
-
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
NCT00097526 ·Status: COMPLETED
-
A Study to Learn About Recifercept in Patients With Achondroplasia
NCT05659719 ·Status: COMPLETED
-
The Treatment and Natural History of Acromegaly
NCT00001981 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
NCT05353192 ·Status: UNKNOWN ·Phase: PHASE4
-
Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
NCT00006394 ·Status: COMPLETED ·Phase: NA
-
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
NCT04798690 ·Status: RECRUITING
-
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
NCT00121875 ·Status: TERMINATED